VICTORIA, April 25, 2019 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC
PINK: IPATF)
U-Protein Express, a wholly-owned ImmunoPrecise Antibodies
subsidiary, in Utrech, Netherlands, announced that it has obtained an
exclusive license from Stanford
University to manufacture and sell a novel protein, Wnt
surrogate Fc, a substitute for a protein known as Wnt.
Wnt proteins are involved in signalling cells to divide and
develop, and the Wnt surrogate can be used as a growth factor in
cell culture media for, among other purposes, the growing of
organoids.
The exclusive nature of the awarded license ensures that the
Company is the single, global, manufacturer and supplier to offer
the Wnt surrogate Fc to the market. The surrogate can be used not
only as a growth factor in cell culture media for the growing of
organoids but also with other cell lines. With hundreds of research
groups around the world culturing organoids, the market for the Wnt
surrogate Fc is strong.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
company focused on the next generation of antibody discovery, to
deliver the most therapeutically-relevant antibodies, in a shorter
period of time, with the highest probability of succeeding to
clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory
facilities located at the Vancouver Island Technology Park in
Victoria, British Columbia, in
collaboration with its wholly-owned subsidiary operations at
U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in
the Netherlands. The Company
operates globally to offer antibody services from target analysis
to pre-clinical studies.
The services offered to clients include antibody discovery
against a broad spectrum of antigens, including challenging
targets. Amongst these services, the Company offers hybridoma
production, B-cell services, and a variety of phage display
platforms. The Company also provides a broad range of supporting
services including immunologically-based assays, recombinant
protein manufacturing, humanization, optimization, stable cell line
development, and advanced solutions to challenges faced by clients
in antibody-related research and development. The antibodies
produced by ImmunoPrecise target a wide variety of therapeutic,
diagnostic and research applications.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30, 2017 which can be accessed at
www.sedar.com. The "forward-looking statements" contained herein
speak only as of the date of this press release and, unless
required by applicable law, ImmunoPrecise undertakes no obligation
to publicly update or revise such information, whether as a result
of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.